Mer­ck­'s PD-1 star Keytru­da flunks a key sur­vival end­point in SCLC — cue the un­fa­vor­able Tecen­triq com­par­isons

Mer­ck’s star check­point drug Keytru­da missed a key end­point in their Phase III tri­al as a front­line ther­a­py for ex­ten­sive-stage small cell lung can­cer, fail­ing to pro­vide a sig­nif­i­cant im­prove­ment in over­all sur­vival.

The drug com­bined with chemo did hit the end­point for sig­nif­i­cance in pro­gres­sion-free sur­vival, leav­ing it in a weak but com­pet­i­tive po­si­tion in this hard-to-treat form of can­cer.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER